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Abstract
Background: The assessment and treatment of Premenstrual Dysphoric Disorder (PMDD) in the
female population is an important issue to be examined. Upward to thirty percent of all females’
report symptoms of moderate to severe PMDD. Proper assessment, identification and treatment
of PMDD as a differential diagnosis by healthcare providers is essential for the effective
treatment PMDD.
Purpose: To provide evidenced based education to mental health professionals for the
assessment and treatment of PMDD in order to help improve the quality of life for patient’s
living with this disorder.
Methods: The PMDD education intervention took place at a inpatient psychiatric unit from
October 2019 to April 2020 to a multidisciplinary team consisting of psychiatrists, psychologists,
nurses, mental health counselors, and social workers during a Grand Rounds presentation at a
state-run psychiatric facility in the Northeast. The participants completed a Likert survey that
assessed the effectiveness of the presentation and the participant’s attitudes towards the treatment
of PMDD.
Results: Post intervention, participants reported improved knowledge regarding assessment and
evidence based modalities for the treatment of PMDD
Keywords: Premenstrual Dysphoric Disorder, Adolescents, Self-harm and
Depression
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Considering Premenstrual Dysphoric Disorder
as a Differential Diagnosis in the Psychiatric Population
An Educational Intervention Project
Introduction
Up to 80 percent of women experience some form of Premenstrual Dysphoric Disorder
(PMDD) (Yonkers et al., 2005). Symptoms occur principally during the late luteal phase of the
menstrual cycle, but in the first 2 or 3 days of the follicular phase in about one-third. These
symptoms can include: changes in mood, anxiety, decreased interest in pleasurable activities and
impaired sleep (American Psychological Association, 2013). This project’s goal of educating
mental health providers about PMDD is to increase awareness of the condition and to provide
information and education regarding the patient’s menstrual health so that appropriate
interventions may be implemented individually. Through ongoing assessment and treatment
women who have this condition can have an improved quality of life.
Background
“Premenstrual Dysphoric Disorder is a severe negative reaction to the natural rise and
fall of estrogen and progesterone.” (International Association for Premenstrual Dysphoric
Disorder, 2019). The symptoms of this disorder include not only physical manifestations such as
bloating, acne, and mastalgia, but emotional dysregulation.
According to Halbreich, Borenstein, Pearlstein & Kahn, (2003), almost six percent of
young women live with this disorder. When this important disorder is not recognized or treated
young women are placed at increased risk of mood instability, self-harm and agitation. Without
proper assessment and treatment young women are at risk for impaired well-being and health.
Many healthcare providers come into contact with women who suffer with this disorder on a
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daily basis. These healthcare providers have conversations, discussions and opportunities for
patient education. So for the purpose of the DNP project, education will be done with mental
health care providers so that conversations can be had with women about their reproductive wellbeing and how it relates to mood.
Problem Statement
The relationship between the occurrence of Premenstrual Dysphoric Disorder
(PMDD)and young women who self-harm and have emotional dysregulation is not clearly
understood. The purpose of this DNP project was to provide education to healthcare
professionals so that there was an improvement in diagnosis, assessment and treatment of PMDD
in the inpatient setting by education about the disorder, treatment standards and utilization of an
evidenced based tools (Usher, 2102). It has been hypothesized by medical professional that
changes in hormones can affect mood in women during child bearing years (Gosh, 2103). It is
questioned whether these fluctuations in mood states can increase the likelihood of self-harm,
agitation and mood lability. The DNP student provided education about assessment and
treatment as well as how to create a dialogue with patients about PMDD to a multidisciplinary
mental health care provider audience.
Organizational “Gap” Analysis of Project Site
The project site provides treatment for 360 patients who have not been able to stabilize
psychiatrically in a lower level of care. This site serves as the highest level for psychiatric care in
the Commonwealth of Massachusetts. The patients admitted have psychiatric diagnoses that
range from thought and mood disorders to Post-Traumatic Stress Disorder (PTSD). While
PMDD may be part of a differential diagnosis, it is not formally assessed using an evidence
based tool. Historically, the presence of this disorder has been minimized (Yonkers et al, 2005).
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Currently, nursing staff at the hospital completes a detailed assessment at admission, but does not
complete a reproductive health assessment and do not ask questions pertaining to mood and
hormonal fluctuations. The goal of this project was to educate mental health professional staff to
become familiar with this PMDD as a differential diagnosis in mental health care and for the
mental health professional staff to become familiar with evidenced based tools that can be
utilized in the inpatient setting, as well as diagnostic criteria and treatment options. These tools
included scales that can be used by patients to rate their symptoms, as well as symptom rating
scales that can be used in assessment by healthcare providers. In doing, this the health care
provider will be better informed to advocate and educate their patient population
Review of the Literature
The relationship between the occurrence of Premenstrual Dysphoric Disorder (PMDD)
and young women is not clearly understood as a differential diagnosis. The purpose of this
literature review was to examine some of the current evidence based research on the complex
relationship between PMDD and related behaviors in young women and support the further need
for proper education, assessment and treatment.
Changes in hormones can affect mood states in women of child bearing years (Usher,
2012). It is also now thought these changes may impact the emotional health of the young
women and can lead to increased agitation and self-harm behaviors. (Yonkers et al, 2005) For
the purpose of the analysis of the quality of the evidence used in the review of literature the
Johns Hopkins Nursing Evidence-Based Practice Model (JHNEBP) is utilized. The JHNEBP is a
tool that uses a three step process to examine the quality of evidence based literature and how it
translates to practice (Newhouse, Dearholt, Poe, Pugh, and White, 2005).
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The following databases were used to obtain to the journal articles reviewed: Google
Scholar, PyschINFO, PUB MED. Terms used included Premenstrual Dysphoric Disorder,
Adolescents, Emotional Dysregulation, Lability and Self-Harm. The results were limited to
articles or research studies that have taken place over the past ten years, unless the article is
clinically significant (as with the case with Yonkers, et al). Aspects such as culture or nation of
origin of publication were included to look at this as shared phenomenon.
Using the final inclusion criteria for the purpose of the literature review, over thirty
journal articles were found to be appropriate to the needs of this educational intervention. The
final inclusion criteria included articles from scholarly journals that were relevant to effects of
PMDD on Mood. All articles included for the purpose of this project were assessed using the
JHNEBP
In the evidence based studies that were reviewed, there appears to be a relationship
between menstrual cycle, agitation, mood lability and self- harm. In a correlational study looking
at the relationship between depression and relationship between Major Depression and PMDD
(Corbsa et al, 2008) showed that Major Depression in itself can cause symptoms of PMDD.
Furthermore, Corbsa et al, hypothesized that decrease in mood and increase in depression can led
to thoughts of self-harm, agitation and suicidal ideation.
Looking beyond a depressed mood state related to menses and self-harm, it can be
supported that menses and bipolar disorder can contribute to self-harm actions and agitation. A
case study by Gosh (2013), found that in bipolar disorder women could also have premenstrual
exacerbations, causing diagnostic confusion. When in a hypomanic or mixed episode state a
patient may have showed impaired judgement leading to intentional or unintentional self-harm
and agitation.
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Saunders and Hawton (2006), evaluate the evidence between the relationship of menses
to non- suicidal self-harm behaviors. They contributed this to the role of estrogen and the
serotonergic system between the menstrual cycle and non-fatal suicidal behaviors and
interactions between estrogen and the serotonergic system. Saunders and Hawton, conducted a
systematic review of forty-five separate research studies on the effects of the menstrual cycle and
suicidal ideation, self-harm and emotional dysregulation. In review of these studies, they
observed that there is a relationship between cycles and self-harm, rather than a causal effect.
According to Faticia et al (2018), the relationship between psychosis and PMDD is
evident because of the decline of estrogen during the late luteal phase of the menstrual cycle's
late luteal phase, which can worsen psychosis. However, this study does not examine the effects
of estrogen on mood and self-harm. But hypothesis the effects of estrogen on mental status
decline.
In qualitative study out of Lund University, in the United Kingdom, nineteen participants
were interviewed about their healthcare providers understanding about PMDD found that most
participants felt that their healthcare providers had a knowledge deficit about the treatment and
consequences of PMDD on their patients (Jurvanen, 2017). This study further found that most
women experiencing PMDD felt that their healthcare providers did not acknowledge how PMDD
affected their daily functioning and work performance.
Current best practice for treatment of this disorder include the use of oral contraceptive
and SSRI’s (Yonkers et al, 2005). In a recent publication by the International Association for
Premenstrual Disorders (2019), current recommendations include the potential incorporation of
antidepressant medications such as Prozac, Paxil, or Celexa, these medications have been shown
to have efficacy rate of Strong evidence of in the treatment of PMDD in many randomized
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controlled trials are around 60-75%. Use of continuous oral contraceptives have been shown
reduce PMDD symptoms in controlled trials 48% of time (Yonkers et al, 2005). Currently,
studies are being completed with the use of continuous hormonal release IUDs such as mirena
and low dose antipsychotics such as Seroquel.
Why is understanding the relationship between menstruation, mood lability, agitation and
self-harm important for the Mental Health Care provider? Barry (2018), believed that by utilizing
an evidenced based tool that eventually one can predict changes in mood related to menses and
reduced changes in mood, agitation and self-harm behaviors by delaying one’s menses (use of
oral contraceptives) or by the addition of a SSRI. When we are able to better understand how
lability of mood related to menses impact we can reduce the risk of our patients engaging in selfharm behaviors. This reduction in self-harm behaviors and reduction of symptomology can
provide relief from the agonizing nature of not being able to predict or stabilize one’s mood.
Through further study of PMDD in the young female population the Mental Health Care
provider can create opportunities for providing education to patients and encourage patients to
take ownership for their own health and well-being by embracing their reproductive health.
Evidence Based Practice:
Current Evidence Based Practice guidelines do not recognize PMDD as a disorder
outside the United States. As of now, the World Health Organization recommends that
Premenstrual Dysphoric Disorder be recognized as a medical condition that is in need of further
research and treatment (Craner, Sigmon, & McGillicuddy, 2014).
According to Panay (2011), current best practice guidelines recommend that patient’s
identified as being diagnosed with PMDD is treated by a multidisciplinary team that incorporates
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medications, nutrition, exercise, and Cognitive Behavioral Therapy (CBT) to have the best
outcome for management of symptoms.
Theoretical Framework/Evidence
The Biopsychosocial theory takes a holistic approach to looking at the individual that
encompasses the different components that make up wellness (Alfonso, 2004). Current best
practice guidelines state that PMDD should be treated by a multidisciplinary team and that the
patient should be treated holistically and that complementary therapies are helpful for maximum
alleviation of symptoms and wellness (Panay, 2011). Chrisler (2008) describes the female
menstrual cycle as being a “perfect process” that takes in account the female’s physiological
status and how it can be affected by behaviors and experiences (pg.65).
According to Walker (1995), when we view PMDD through a Biopsychosocial model, we
become better aware of the patient’s individual experiences and we gain a clearer understanding
of their lived experience. Biopsychosocial theory takes into account the patient as a whole. It is a
holistic approach that appreciates the different dynamics in the patient’s life that effect their
health and wellbeing.
Methods
A Quality Improvement education intervention was implemented in order to educate
mental health care providers regarding Premenstrual Dysphoric Disorder. During a recorded
sixty-minute presentation offered at a hospital wide Grand Round, 30 healthcare providers were
presented with how to properly assess for PMDD and gained knowledge on differential
diagnosis, and appropriate treatment to reduce suffering to patients.
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Goals, Objectives and Expected Outcomes
The goals and objectives of this DNP project were:
Goal: Mental Health Care Providers were able to gain knowledge in the signs and symptoms
identification, assessment and holistic treatments of PMDD for patients with mental health
disorders.
Objectives and Outcomes:
I.

Education- The participants were able to verbalize the signs and symptoms of PMDD

after completing the Grand Rounds.
II.
III.

Assessment- All participants were trained on how to complete a PSST-A.
Collaboration- Reinforcement about the importance of assessment and treatment of this

disordered by all providers involved in the patient’s treatment team.
Expected Outcome: resulted in increased participant awareness of PMDD as evidenced by the
staff being able to verbalize signs and symptoms of PMDD by self-report on Likert survey.
Ethical Considerations/Protection of Human Subjects
The University of Massachusetts, Amherst (UMass) Internal Review Board (IRB)
approval was obtained prior to initiating the educational intervention, quality improvement
project. The results obtained from the data analysis was aggregated and did not include any
potential participant identifiers. The data was scored on a password protected laptop computer
that was only accessible by this DNP student. The risks to those participating in the project were
no greater than those who are not currently being assessed for PMDD. All participants’ right to
privacy of health information was protected by the Health Insurance Portability and
Accountability Act of 1996 (HIPPA).
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Implementation and Population
The implementation phase of this project started September 2019. The DNP student obtained
approval via the education coordinator and ground rounds committee to conduct a presentation
about PMDD criteria, diagnosis, assessment and treatment. Specific Learning objectives were
developed for the presentation with input from the hospital’s grand round committee.
In January 2020, the DNP student conducted a 60 -minute power point presentation on
PMDD during a Grand Rounds presentation at a state run psychiatric inpatient facility in the
Northeast. The audience consisted of psychiatry, psychology, nursing, social work and mental
health. All Health Care Providers were eligible to received Continuing Education Units (CEUs)
for attending the presentation. Of the 30 participants, seventeen returned completed surveys. The
following table (Table 1) represents the breakdown of the Mental Health Providers disciplines
that took part in the education intervention.
Table 1
Mental Health Discipline of Participants
Discipline

Participants

Percentage

Psychology

0

0.0%

Psychiatry

4

23.53%

Nursing

2

11.76%

OT/Rehab

2

11.76%

LMHC

1

5.88%

Social Work

7

41.18%

Other

1

5.88%

14

The majority of the participants that completed the survey were non-nursing mental
health care providers. Of the 17 mental health care providers, 41% (n= 7) identified as Licensed
Social workers, 23% Psychiatrist or APRNs (n= 4), 11% (2) Occupational Therapists, and one
Licensed Mental Health Counselor.
The Premenstrual Symptom Screening Tool-Adolescent (PSST-A) version was utilized to
assist in teaching participants on the assessment of the symptoms of Premenstrual Dysphoria
Disorder. The PSST-A is an evidence based and reliable tool that helps healthcare workers
evaluate the presence of Premenstrual Symptoms and how these symptoms impact the daily
functioning of patients. Additionally, a patient tool kit was disseminated to all participants
consisting of resources to assist in the diagnosis, assessment and treatment of patients (see
Appendix E). The tool kit contents for patient education included copies of the PSST-A, diary
card of symptomology, brochures on PMDD, and listings of web based support groups.
Following the presentation, all members of the multidisciplinary audience received a
Healthcare Provider Survey sent to them by the writer via survey monkey shortly after the
presentation and also one month later via email to assess change in clinical practice after the
educational intervention was conducted.
Measurement Instruments
In order to measure the outcomes of this DNP Project, the following instruments were
used HealthCare Provider Quest and Follow Up one month post educational intervention Health
Care Provider Questionnaire The first instrument was a DNP student developed survey
(Appendix D) with eight Likert scale questions. A five point Likert scale of 1 to 5 was used to
obtain opinions from the participants. The scores were given based upon the following numbers:
1= strongly disagree; 2= disagree; 3= neither or N/A; 4= agree; and 5= strongly agree. The
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survey was designed to illicit the opinions of the nursing staff on the usefulness and benefit of
assessment and treatment of PMDD. Additionally, this survey queried the discipline of the
audience member, attitudes towards discussing PMDD with their patients, the relevance of
PMDD in the treatment of patients, and the usefulness of the grand rounds presentation. The
following were the eight questions administered to the participants via Survey Monkey.
1. Overall Rating of Educational Activity presentation quality
2. Do you plan to make any changes in practice based on this educational intervention?
3.

Are you able identify the signs and symptoms of PMDD after the presentation?

4. Do you feel that you are more knowledgeable about the impact of PMDD on your
patient’s health?
5. The number of staff that feel that PMDD is an under recognized condition?
6. Did you find the tool kit helpful?
7. Do you feel that your patient’s benefit from being assessed for PMDD?
8.

Do you feel more comfortable talking to your patients about their PMDD symptoms after
the presentation?
A second follow up survey was developed by the DNP student and sent out to all

participants one month post educational intervention allowing them to provide comments via an
anonymous Survey Monkey email on the educational intervention. This survey was to examine
how the educational presentation informed their continued practice. Two questions were asked
of all participants to identify themes and viewpoints on the treatment of PMDD, which are
included below:
1. Have you incorporated assessing for PMDD into your practice based upon what you
learned in the presentation?
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2. Do you feel more confident in talking to your patients about PMDD since the
presentation?
The two surveys were completed anonymously online via Survey Monkey. Descriptive
statistics, such as frequency, mean, and median were used to analyze the data. Furthermore, the
participants’ responses were analyzed utilizing these descriptive statistics to assess for
knowledge improvement after the Grand Rounds presentation. Additionally, the Likert questions
in the Health Care Provider questionnaires were scored to quantify the extent to which the Health
Care Providers agreed with the questions asked.
Results
The Presentation “Considering Premenstrual Dysphoric Disorder as Differential
Diagnosis in the Psychiatric Population” was a sixty-minute educational presentation and
intervention that took place at 360 bed inpatient psychiatric hospital in the Northeast. The
participants that attended this intervention were mental health providers, working with patients
with chronic mental health disorders. The data collected by the survey will be discussed in the
subsequent sections which are divided by questions asked of the participants and their responses.
Initial Survey Monkey Results
1. Overall Rating of Educational Activity presentation quality
The majority of participants viewed the presentation favorably, with 16 of the 17 participants
reporting that the presentation was excellent with to very good, one out 17 of the participants
indicated that the presentation of the educational intervention was fair. As a major goal and
objective of the educational intervention, the DNP student wished to see increased awareness
and education regarding PMDD amongst mental health care providers. This awareness of the
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importance of making changes in practice was demonstrated by the participant’s desire to
include assessment for PMDD in their standard of practice.
2. Do you plan to make any changes in practice based on this educational intervention?
70% (n= 15) of the participants indicated a plan to make changes in their practice to
incorporate the assessment of PMDD into the care of patients. While 17% (n= 2) of
participants did not feel the need to change their practice after the intervention. This may be
related to their own practice currently incorporating assessment and treatment of patients
with PMDD.
3. Do you feel that you have improved identification of signs and symptoms of PMDD
after Presentation?
The members of the multidisciplinary audience that attended were able to verbalize the signs
and symptoms of PMDD after attending the Ground Rounds as evidenced, by all participants
reporting that after the educational intervention that they felt increased awareness of PMDD
was shown. Also, all participants (n= 17) were able to self-identify at least three signs and
symptoms of PMDD. While 88% (n= 16) of participants were able to identify and three
evidence based approaches to the treatment of PMDD.
4. Can you identify how PMDD impacts your Patients’ health and wellbeing?
All participants (n= 17) report that they were able to identify two areas that PMDD can
impact a patient’s co-morbid psychiatric illness. The participants were also asked if they
believed that the information presents at the educational intervention utilized the most
current and best evidence available. All participants also reported that they felt that the
information that was presents used the best evidenced based materials and literature
possible.
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5. Do you feel that PMDD is an under recognized disorder that benefits from assessment?
All participants reported that they felt patients could benefit from being assessed for PMDD.
Furthermore, 88% (n= 16) felt that PMDD is an under recognized disorder that benefits from
ongoing assessment and treatment.
6. Do you feel more comfortable in talking to your patients about their PMDD symptoms
after the presentation?
All participants (n=17) reported that they felt more comfortable talking to their patients
about PMDD symptoms after the presentation. To encourage continued conservation and
assessment all participants received educational materials to take with them to help provide
education to their patients about this disorder. These materials included record for the
patients to assess their own symptoms, a PowerPoint copy of the presentation, a copy of the
PSST-A, and patient education materials.
7. Did you find the tool kit helpful?
Regarding the helpfulness of the PMDD tool kit, 82% (n= 15) found the “tool kit” helpful
and would use the resources provided to assess, treat and educate their patients. Conversely,
two participants did not find the tool kit helpful, reporting that the font utilized on the
handouts were too small to read.
One month follow up Health Care Provider Survey Monkey Questionnaire
1.Have you incorporated assessing for PMDD into your practice based upon what you
learned in the presentation?
At the one month follow up second survey, three of the thirty participants returned a follow
up survey, it is unknown why there was limited participation These results showed that two
of the three respondents have incorporated assessment of PMDD into their individual
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practice with their patients. Additionally, these same three participants felt more confident in
talking to their patients about PMDD as evidenced by reporting increased confidence in their
assessment skills.
3. Do you feel more confident in talking to your patients about PMDD since the
presentation?
Increased interest in the topic of PMDD as a differential diagnosis in the psychiatric
population was demonstrated, with all three participants reporting increased interest in
continued education about PMDD. However, with limited data one month after the
intervention it was difficult to see if the intervention impacted all the practice of the
participants.
Further information and dissemination of education related to the care of the PMDD
patient needs to be clarified as limited data and feedback was able to be collected after the
initial intervention.
Discussion
A presentation on PMDD took place during a sixty-minute Ground Rounds at a 360 bed
inpatient psychiatric hospital in the Northeast. The goal of this presentation was to provide
evidenced based education to mental health professionals for the assessment and treatment of
PMDD. It is through education that we can improve the quality of life for patient’s living with
PMDD. After the presentation, all participants received a questionnaire to examine their views
on PMDD.
The initial survey had good participation with 17 Mental Health Care Providers
completing it. These Mental Health Care Providers received CEUs upon completion. However,
at the one month follow up, a second survey was emailed to participants with limited returned
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surveys by the Health Care Providers. Of the 17 participants, only three returned completed
surveys. Moreover, it is believed that the low return rate was due to the lack of incentive for
providers to complete the second survey. Nevertheless, the second survey assessing PMDD data
resulted in the following themes discussed in subsequent paragraphs.
Knowledge Deficit in the assessment and treatment of PMDD
In the initial follow survey, 70% of the participants reported that they would change their
practice after the presentation. In the follow up survey, all participants reported that incorporate
assessment for PMDD into their individual practice. This response rate was an indication that the
Health Care Providers pre intervention knowledge of the assessment of PMDD and treatment
was limited. Also, this further indicated that the participants benefited from learning about the
impact of PMDD on their patients.
Under recognition of PMDD by Health Care Providers
All Health Care Professionals that completed the initial survey reported that they believed
that PMDD is an important disorder to assess for and treat for individuals with mental health
disorders after the presentation. The Mental Health Providers also endorsed the concept that
PMDD is not widely recognized as mental health disorder that impacts patient health and
wellbeing. In reviewing the literature, most women experiencing PMDD felt that their healthcare
providers did not acknowledge how PMDD affected their lives (Jurvanen, 2017). Through
ongoing education of mental health care providers this under recognition could be reduced and
the quality of care can be improved.
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Education creates confidence in communication
As indicated by the data collected in both the initial and follow up survey, all participants
reported gained confidence in talking to their patients about assessment and treatments of
PMDD.
Walker (1995), stated that we must see our patients living with PMDD with a holistic and
multidisplinary lens so we can communicate empathically with our patients. As evidenced by the
participant feedback from survey further education and communication about PMDD is
imperative in providing holistic care. Through effective communication patients can be more
comfortable in disclosing their symptoms to their providers.
Recommendations
The importance of further study into the phenomenon of PMDD is essential. Through
training healthcare providers how to properly assess for PMDD and understand the criteria for
PMDD as a differential diagnosis, healthcare providers can provide appropriate treatment and
reduce suffering to our patients, this is the goal of nursing. Additionally, it is recommended that
ongoing education about the most current evidence based treatments and modalities for PMDD
be reviewed on an annual basis with all Mental Health Care Professionals at the facility to
maximize the benefits of this intervention
Premenstrual Dysphoric Disorder is a serious concern to the wellbeing of women of
childbearing years. When PMDD is not treated properly there is an increased risk of harm to the
patient. PMDD can cause mood instability, self-harm and agitation in some affected patients
(Yonkers et al, 2007). For young women who are struggling with mental health issues such as
Post-Traumatic Stress Disorder, Bipolar disorder or psychosis, PMDD can intensify these issues.
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Conclusion
The assessment and treatment of Premenstrual Dysphoric Disorder (PMDD) is an
important issue to be examined. According to research, up to thirty percent of all females’ report
symptoms of moderate to severe PMDD. Proper assessment and treatment of PMDD as a
differential diagnosis in psychiatric assessment is essential for patients to receive adequate care.
Without proper assessment and treatment, patients are at higher risk for impaired job
performance and activities of daily living (Jurvanen, 2017).
The goal of this DNP project was to increase awareness about the importance of
assessing menstrual health so that appropriate interventions may be implemented. By assessing
for and treating PMDD we can improve the quality of life for our patients that may be
experiencing mood lability or thoughts of self-harm due to hormonal sensitivity.
.
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Appendix A
Cost Table

Time for staff training
Reproduction of Tool kits for staff and patient use=$100
Use of Laptop –Provided by DNP student
Event space= free providing by hospital
Total cost for Quality Improvement Project= $100
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Appendix C
Timeline
Table 1
Task
Education
and
Presentation
of Nursing
staff on
PMDD.
Teaching of
the PSST-A
Aggregation
of the data
Post
intervention
meeting with
collaborating
nurses
Analysis of
the results
and outcomes
Presentation
of the results
to nursing
and program
staff

October

November

December

January

February

March

X

X

X

April

X
X

X
X

X
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Appendix D
Healthcare Provider views on Premenstrual Dysphoric Disorder Assessment
Please complete the following survey with specific regard to the above enquiry, by placing a
circle on the appropriate response that best applies to you. Select only one response per
question. The responses are on a 5-point Likert scale with 1= strongly disagree; 2= disagree; 3=
neither or N/A; 4= agree; and 5= strongly agree. Please do not write your name or date of birth
on this survey. All responses are kept confidential.
1. Do you feel that PMDD is an under recognized condition?
Strongly disagree
disagree neither
agree strongly agree
2. Do think that your patient’s benefit from being assessed for PMDD?
Strongly disagree

disagree

neither

agree strongly agree

3. Do you feel comfortable talking to a patient about their PMDD symptoms?
Strongly disagree

disagree

neither

agree strongly agree

4. Do you feel that your knowledgeable about PMDD prior to attending this presentation?
Strongly disagree

disagree

neither

agree strongly agree

5. Did you find the handouts and tool kit helpful for you and your patients”
Strongly disagree

disagree

neither

agree strongly agree

6. Do you feel that your patients would benefit from educational materials about PMDD?
Strongly disagree
disagree
neither
agree strongly agree
7. What is your discipline?
Psychiatry Psychology OT/Rehab MHC/MHW
7. Comments

Nursing
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Appendix F

Evidenced Based Literature Tool Kit for Professionals

Evidence-Based Management of
Premenstrual Disorders (PMDs)
Note: this guide is intended primarily as a resource for health care providers.
If you are a patient, we recommend you also check out our treatment options
page designed for patients at iapmd.org/treatment-options.
Premenstrual disorders such as premenstrual dysphoric disorder (PMDD) and
premenstrual exacerbation (PME) of psychiatric disorders are complex to
diagnose and treat. Below, we provide guidelines to help health care
providers educate and treat their patients effectively.
Assessment and Diagnosis of PMDs: Ultimately, each patient with
premenstrual symptoms is unique, and deserves a compassionate health care
provider who will work with them to find an effective treatment--or set of
treatments-- for their unique needs. Given that PME often predicts poor
response to first-line PMDD treatments (see below), prospective diagnosis
using two months of daily symptom ratings is recommended to differentiate
between PMDD (symptoms present only premenstrual), PME (symptoms
always present but worsened premenstrual), and non-cyclical symptoms.
Daily ratings can also be continued in the context of treatment in order to
evaluate effectiveness over time. A daily symptom rating form can be
downloaded at https://iapmd.org/provider-resources. Standardized scoring of
these daily ratings to determine diagnosis can be accomplished using the CPASS scoring system available at https://iapmd.org/c-pass. Please note that it
is possible to have both PMDD (five symptoms that are present only in the
luteal phase) and also PME of other underlying disorders.
Treatment of PMDs: Since this is a relatively new area of medical science,
the number of randomized controlled trials for PMDs remain relatively small.
However, several treatments have been found to be effective, and more are
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currently under investigation. Many patients utilizing IAPMD services have
already tried many of the treatments below with no relief, whereas others
have tried none. The purpose of this page is not to provide a “one-size-fitsall” recommendation for the treatment of premenstrual disorders; rather, it is
to help those seeking information about effective treatments by reviewing the
best evidence about general efficacy and safety of each treatment in those
with premenstrual disorders.
Please visit iapmd.org for more information and resources. This guide was
prepared by the IAPMD Clinical Advisory Board, under the direction of Dr.
Tory Eisenlohr-Moul.
© 2019 International Association for Premenstrual Disorders
http://iapmd.org | updated March 11, 2019

Evidence-Based Management of Premenstrual Disorders
(PMDs) page 2
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I.

Premenstrual Dysphoric Disorder (PMDD)

PMS is related to a variety of physical and psychological symptoms that occur just before your
menstrual period. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS.
1.
What is PMS?
Premenstrual syndrome (PMS) is a medical condition that affects some women of childbearing
age. More than one in three women suffer from PMS. One in 20 suffer so severely that their
lives are seriously affected. PMS is related to a variety of physical and psychological symptoms
that occur just before the menstrual period.
2.

What causes PMS?

The exact cause of PMS is unknown, but it seems to be related to the fluctuating levels of
hormones (including estrogen and progesterone) that occur in preparation for menstruation.
3.

What are the symptoms of PMS?

There are many symptoms of PMS, and the number and severity of symptoms vary from
woman to woman. In addition, the severity of the symptoms can vary from month to month.
Common symptoms of PMS include:
●
●
●
●
●
●
●
●
●
●
●

Bloating
Breast tenderness
Weight gain
Trouble concentrating
Headaches/backaches
Skin problems/acne
Fatigue
Tearfulness
Irritability/aggression
Anxiety
Mood swings and/or depression
4.

How is PMS diagnosed?

There is no single test to diagnose PMS. It is a clinical diagnosis which is made by discussing
your concerns with your doctor. However, there are some strategies your doctor may use to
help diagnose PMS. These include:
PMS symptoms diary — Your doctor may ask you to keep a diary to assess the frequency and
severity of symptoms. By doing this, you can see if your symptoms correspond to certain times
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in your monthly cycle. While your symptoms may vary from month to month, a trend likely will
appear after tracking your symptoms for a few months. Sometimes women are surprised to
find that the symptoms do not seem to vary with the fluctuation of their hormonal cycles.
Women who have many of the emotional symptoms throughout the month may actually suffer
from depression and/or anxiety. Making a correct diagnosis is the most important first step
towards feeling better.
Thyroid testing — Because thyroid disorders are common in women of childbearing age, and
some of the symptoms of PMS—such as weight gain, depression, fatigue—are similar to
symptoms of thyroid disorders, your doctor may order a test to evaluate thyroid function. This
can help to rule out a thyroid disorder as a cause of your symptoms.
5.

How is PMS treated?

Treatment for PMS is based on relieving symptoms. Treatment begins with a thorough
assessment of your symptoms, as well as the impact of them on your daily life.
Education — You will be better able to deal with your symptoms if you can relate how you're
feeling to your menstrual cycles, knowing that you will feel better once your period starts.
While symptoms may vary from month to month, the symptoms diary mentioned above can
give you a good idea of how your periods affect your physical health and moods. Learning how
to cope with the problems in your life may help relieve the stress and irritability you feel before
your period. If you experience severe anxiety, irritability, or depression, counseling and/or
medication may be helpful.
Nutrition — A healthy diet is important to overall physical and mental wellness. Making
changes in your diet—including reducing the amount of caffeine, salt and sugar and staying
well-hydrated with water and light juices—may help relieve symptoms of PMS. A number of
vitamin supplements are often taken to try to help PMS symptoms, including vitamin B6,
vitamin E, calcium, and magnesium. However, none of these supplements have been shown in
well-designed studies to be better than placebo (sugar pills or dummy pills, which can help 30
percent of the time without an active ingredient). Talk to your doctor about the safety of trying
calcium or magnesium supplements for you. Excess vitamin E or vitamin B6 is usually
discouraged due to studies showing concerns about side effects, especially with vitamin B6.
This vitamin can cause permanent nerve damage in women with daily doses in excess of 50 mg
per day. It is best to try to get your vitamins by eating a diet rich in unprocessed fruits and
vegetables.
Exercise — Like a healthy diet, regular exercise can improve your overall health. It also can help
relieve and help you cope with the monthly symptoms associated with PMS, especially
dysmenorrhea (painful cramping and bloating).
Medications — Over-the-counter pain relievers—such as aspirin and ibuprofen—may help
relieve symptoms such as headache, backache, cramps, and breast tenderness. Make sure you
have no contraindications such as peptic ulcer disease or kidney disease before using many pain
relievers. Medications may be prescribed in cases of depression or anxiety that are disruptive to
a woman’s lifestyle. Birth control pills and other hormonal contraceptives can help by
controlling the hormonal fluctuations of the monthly cycle.
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6.

Can PMS be prevented?

PMS itself cannot be prevented, but through education and appropriate treatment of
symptoms, most women can find relief. A healthy lifestyle—including exercise and a proper
diet—also can help a woman better manage the symptoms of PMS.
7.

What is PMDD?

Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. The symptoms of PMDD are
similar to those of PMS, but are severe enough to interfere with work, social activities, and
relationships.
8.

How is PMDD diagnosed?

PMDD is diagnosed when at least five of the following symptoms occur seven to 10 days before
menstruation and go away within a few days of the start of the menstrual period:
●
●
●
●
●
●
●
●
●

Mood swings
Marked anger
Irritability
Tension
Decreased interest in usual activities
Fatigue
Change in appetite
Sleep problems
Physical problems, such as bloating

Before a doctor makes a diagnosis of PMDD, he or she will rule out other emotional disorders—
such as major depression or panic disorder—as the cause of the symptoms. In addition,
underlying medical or gynecological conditions (such as endometriosis, fibroids, menopause,
and hormonal problems) that could account for symptoms must be ruled out.
9.

How common is PMDD?

PMDD occurs in 3 to 5 percent of menstruating women. Women with a personal or family
history of mood disorders—including major depression or postpartum depression—are at
greater risk for developing PMDD.
10.

What causes PMDD?

As with PMS, the exact cause of PMDD is not known. Most researchers, however, believe PMDD
is brought about by the hormonal changes related to the menstrual cycle. Recent studies have
shown a connection between PMDD and low levels of serotonin, a chemical in the brain that
helps transmit nerve signals.
Certain brain cells that use serotonin as a messenger are involved in controlling mood,
attention, sleep and pain. Therefore, chronic changes in serotonin levels can lead to PMDD
symptoms.
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11.

How is PMDD diagnosed?

Clinical evaluation should include a comprehensive review of the patient's symptoms and
medical history, a physical exam, a gynecologic exam, and basic laboratory tests as needed.
Psychiatric evaluation should focus on symptoms of depression, seasonal variation of
depression (looking for worsening in the winter), alcohol and drug use, early victimization and
trauma, family history of affective disorder (a group of disorders characterized by a disturbance
of mood), alcoholism, and current situational stresses.
12.

How is PMDD treated?

Many women gain relief from the symptoms of PMDD with education and lifestyle changes
including exercise, vitamins, and a caffeine-free diet. Medications, including anti-depressants
like selective serotonin reuptake inhibitors (SSRIs), may be used to treat the emotional
symptoms of PMDD. Hormonal contraceptives may help, though it is important to be patient
until a right fit for the woman’s body chemistry can be found. The optimal hormonal
option/method can vary between each person. The FDA has approved the birth control pill Yaz®
for the treatment of PMDD. However, other oral contraceptives may also help a woman with
PMDD. In addition, individual and group counseling, and stress management can be beneficial
in helping a woman cope with PMDD.
SHARE Facebook Twitter LinkedIn EmailPrint
13.

Related Institutes & Services

(1)
Ob/Gyn & Women's Health Institute
Find the latest information on Women’s Health, including the use of minimally invasive surgical
techniques, treatments for infertility, menstrual disorders, urogynecology and pelvic floor
disorders, menopause and more.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support
our mission. We do not endorse non-Cleveland Clinic products or services. Policy
14.
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